Stereotaxis (NYSE: STXS) has announced that it has entered into a definitive agreement to acquire closely held Robocath, a venture-backed innovator of robotic techniques for interventional cardiology and neurointerventions, based in France.
According to Stereotaxis, the acquisition strengthens its leadership position in endovascular care by combining technologies into fully integrated robotic solutions for electrophysiology, interventional cardiology and neurointerventions.
In a statement, David Fischel, chairman and CEO of Stereotaxis, commented, “Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures. By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine. This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, opens new avenues for growth, and supports other strategic opportunities being pursued by Stereotaxis.”
